Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Protecting People

A vial labeled hemophilia
Protecting People and preventing complications of Blood Disorders.

Download and print this page [PDF – 652 KB]

1 in 76 Americans are born with a blood disorder.

People with blood disorders are living longer than ever before, but with far too many medical complications that could be prevented. These conditions have serious, sometimes fatal, health consequences and cost our healthcare system billions of dollars every year. CDC’s National Center on Birth Defects and Developmental Disabilities (NCBDDD) invests in activities that increase understanding of blood disorders, advance medical care and treatments, and improve outcomes for all people with blood disorders.

Funding Chart of Blood Disorders Investment Total $15.1 million. Comprised of $5 million Hemophilia Treatment Centers. $4.5 million Public Health Approach to Blood Disorders. $3.5 million Hemophilia. $2.1 million Thalassemia.

How NCBDDD makes a difference

Hemophilia Treatment Centers

NCBDDD works with funded partners to implement the Community Counts project in hemophilia treatment centers (HTCs) across the United States, raising participation among all 136 federally-funded HTCs (as of July 31, 2016) to 100% for the HTC Population Profile, 92% for the Registry for Bleeding Disorders Surveillance, and 91% for Mortality Reporting.

Public Health Approach to Blood Disorders

NCBDDD recognized and shared best practices on preventing blood clots in hospitalized patients. NCBDDD supported and coordinated the development of a publication highlighting the public health impacts of SCD on patients, healthcare providers, and healthcare systems, and work being done to improve the lives of people living with SCD.

Hemophilia

NCBDDD supports inhibitor testing as part of the Community Counts Registry for Bleeding Disorders Surveillance, and provided the first-ever estimates of the burden of inhibitors among people in the United States with hemophilia. An inhibitor is a potentially serious health problem affecting people with bleeding disorders that stops or “inhibits” their treatment product from working, which makes it harder to stop or prevent a bleeding episode.

Thalassemia

Thalassemia is a group of genetic red blood cell disorders that cause an anemia beginning at birth and lasting throughout life. As a result of extensive outreach during the past 3 years, enrollment in the thalassemia patient database has increased 27%, reaching 1,014 people diagnosed with this rare disorder.

2017 Successes

  • Better You Know
    NCBDDD partnered with the National Hemophilia Foundation to launch “Better You Know,” a public health education campaign to increase awareness about the signs, symptoms, and diagnoses of bleeding disorders among women. The campaign provided information for healthcare providers and women experiencing heavy menstrual bleeding who may be at risk for having a bleeding disorder. The campaign website has tools to help women determine their risk for a bleeding disorder and next steps to seek care.
  • Second Inhibitor Summit
    In 2017, CDC convened the Second Inhibitor Summit to discuss how inhibitors are monitored and how a tracking system could be better used or improved to prevent inhibitors among hemophilia patients. Prominent leaders in the bleeding disorders community attended the meeting, including care providers, researchers, patient advocacy partners, federal partners, and representatives of pharmaceutical companies.
  • Alpha Thalassemia Webinar
    CDC worked with the Association Public Health Laboratories’ Hemoglobinopathy Work Group to conduct a two-part webinar on Alpha Thalassemia. The series described the different types of Alpha Thalassemias, the importance of reporting the diagnosis and treatment of Alpha Thalassemia, and the current status of Alpha Thalassemia screening across the United States.

One in ten people with a blood clot will die if it moves to the lungs.


Healthcare costs associated with blood clots in the U.S. are $10 billion

Priorities for the future

  • Understanding burden: Harness new tools to analyze electronic health records, state wide monitoring systems, and existing healthcare databases to understand the populations affected by blood clots and hemoglobinopathies.
  • Improving prevention: Work with partners to promote better treatment and follow-up care options for people affected by blood disorders.
  • Empowering people to participate and to learn: Create tools and awareness campaigns to teach Americans about the power they have to prevent blood disorder complications and to find the right healthcare provider.
  • Reducing health disparities: Connect vulnerable populations affected by blood disorders with healthcare centers and support systems to ensure access to consistent and high-quality care.
TOP